That is, screening positive for GAD was associated with an increased likelihood of currently using non-prescribed benzodiazepines while screening positive for agoraphobia was associated with a decreased likelihood of currently using non-prescribed benzodiazepines. The gene discussed is GAD1; the disease is agoraphobia.